HOTH - חוב כולל להון Hoth Therapeutics

Hoth Therapeutics, Inc. (HOTH) focuses on the global transportation of dermatological components for bio-tests, as confirmed by the stock price history, where the debt-to-equity ratio stands at 0.00. Management aims to implement advanced therapies for skin inflammation; however, the business is currently in a cost-intensive research phase, meaning that operational expansion is presently leading to an increase in specific testing expenses.

The stability of Hoth Therapeutics, Inc. (HOTH) depends on the continuity of global supply chains and patent protection amid geopolitical risks. The total liabilities-to-equity ratio measures the degree of leverage, determining the extent to which biopharmaceutical development depends on refinancing costs. By analyzing the current total debt-to-equity ratio on GURU.Markets, an investor assesses the balance between business expansion and the risk of insolvency.